iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
April 04, 2023 16:05 ET
|
iBio, Inc.
BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given...
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
March 31, 2023 08:10 ET
|
iBio, Inc.
– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Treg depletion franchise beyond IBIO-101 – BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc....
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
February 16, 2023 16:48 ET
|
iBio, Inc.
- Company has directed antibodies against a specific region of MUC16 - - Potentially offers a differentiated and effective tool in the fight against cancer - BRYAN, Texas, Feb. 16, 2023 (GLOBE...
iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine
January 05, 2023 08:00 ET
|
iBio, Inc.
BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United...
iBio Announces Closing of $3.5 Million Underwritten Public Offering
December 09, 2022 16:05 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its...
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
December 06, 2022 23:27 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its...
iBio Announces Proposed Underwritten Public Offering
December 06, 2022 16:01 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer...
iBio to Participate in the JMP Securities Hematology and Oncology Summit
December 06, 2022 08:00 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Chief...
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
December 05, 2022 08:00 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two...
iBio Announces CEO Departure
December 02, 2022 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of...